ES2154629T3 - Mutantes t-pa resistentes a la inhibicion por sus inhibidores similares. - Google Patents

Mutantes t-pa resistentes a la inhibicion por sus inhibidores similares.

Info

Publication number
ES2154629T3
ES2154629T3 ES90905081T ES90905081T ES2154629T3 ES 2154629 T3 ES2154629 T3 ES 2154629T3 ES 90905081 T ES90905081 T ES 90905081T ES 90905081 T ES90905081 T ES 90905081T ES 2154629 T3 ES2154629 T3 ES 2154629T3
Authority
ES
Spain
Prior art keywords
mutants
serine protease
inhibition
resistant
similar inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90905081T
Other languages
English (en)
Inventor
Joseph F Sambrook
Edwin L Madison
Elizabeth J Goldsmith
Maryjane H Gething
Robert D Gerard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/434,748 external-priority patent/US5550042A/en
Application filed by University of Texas System filed Critical University of Texas System
Application granted granted Critical
Publication of ES2154629T3 publication Critical patent/ES2154629T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A MUTANTES DE PROTEASA DE SERINA DE LA SUPERFAMILIA DE QUIMOTRIPSINA, ESPECIALMENTE MUTANTES +-PA, QUE SON RESISTENTES A LA INHIBICION POR SUS INHIBIDORES AFINES, COMO EL PAI-1 EN EL CASO DE +-PA, Y GENES QUE LO CODIFICAN. LA PRESENTE INVENCION TAMBIEN SE REFIERE A MUTANTES INHIBIDORES DE PROTEASA DE SERINA, PARTICULARMENTE MUTANTES DE PAI-1, QUE INHIBEN LOS MUTANTES DE PROTEASA DE SERINA DE LA PRESENTE INVENCION, PARTICULARMENTE MUTANTES +-PA, Y GENES QUE LO CODIFICAN. LOS MUTANTES DE PROTEASA DE SERINA Y MUTANTES DE INHIBIDORES DE PROTEASA DE SERINA SON UTILES, POR EJEMPLO, COMO AGENTES FARMACOLOGICOS.
ES90905081T 1989-03-06 1990-03-01 Mutantes t-pa resistentes a la inhibicion por sus inhibidores similares. Expired - Lifetime ES2154629T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31921289A 1989-03-06 1989-03-06
US07/434,748 US5550042A (en) 1989-03-06 1989-11-13 Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors and genes encoding the same and serine protease inhibitor mutants and genes encoding the same

Publications (1)

Publication Number Publication Date
ES2154629T3 true ES2154629T3 (es) 2001-04-16

Family

ID=23241316

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90905081T Expired - Lifetime ES2154629T3 (es) 1989-03-06 1990-03-01 Mutantes t-pa resistentes a la inhibicion por sus inhibidores similares.
ES00109138T Expired - Lifetime ES2185529T3 (es) 1989-03-06 1990-03-01 T-pa resistente a la serpina; mutante; genes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00109138T Expired - Lifetime ES2185529T3 (es) 1989-03-06 1990-03-01 T-pa resistente a la serpina; mutante; genes.

Country Status (10)

Country Link
US (1) US5728564A (es)
EP (2) EP0462207B1 (es)
JP (3) JP2991769B2 (es)
AT (2) ATE199090T1 (es)
AU (1) AU637791B2 (es)
CA (1) CA2047702C (es)
DE (2) DE69033699T2 (es)
DK (2) DK1029921T3 (es)
ES (2) ES2154629T3 (es)
WO (1) WO1990010649A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5866413A (en) * 1989-03-06 1999-02-02 Board Of Regents Of The University Of Texas System Pai-1 mutants
ES2113878T3 (es) * 1989-12-29 1998-05-16 Zymogenetics Inc Proteina c hibrida.
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
GB9011861D0 (en) * 1990-05-26 1990-07-18 Beecham Group Plc Novel compounds
DE69105213T2 (de) * 1990-12-18 1995-05-18 Genentech, Inc., South San Francisco, Calif. Substitutionsvariante des gewebeplasminogenaktivators.
AU664469B2 (en) * 1992-06-03 1995-11-16 Genentech Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
GB9216558D0 (en) * 1992-08-04 1992-09-16 British Bio Technology Modified proteases
US5567602A (en) * 1992-08-12 1996-10-22 Arris Pharmaceutical Corporation Recombinant production of chymase
ES2080657B1 (es) * 1993-09-27 1996-11-01 Britisch Bio Technology Limite Proteasas modificadas.
EP0958833A1 (en) * 1998-05-20 1999-11-24 Erasmus Universiteit Rotterdam Methods and means for preventing or treating inflammation
AUPP508798A0 (en) 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
AU2001238721A1 (en) * 2000-03-03 2001-09-17 Zymogenetics Inc. Human serine protease
US6673623B1 (en) 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
KR20040011480A (ko) 2001-03-22 2004-02-05 덴드레온 샌 디에고 엘엘씨 세린 프로테아제 ｃｖｓｐ14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
EP1379637A4 (en) 2001-03-27 2005-04-06 Dendreon Corp TRANSMEMBRANE SERINE PROTEASE 9 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED, AND METHODS FORMING THEREOF
EP1539942A4 (en) 2001-05-14 2005-10-19 Dendreon Corp A TRANSMEMBRANE SERINE PROTEASE 10 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED AND METHOD THEREOF
US20050137094A1 (en) * 2001-06-11 2005-06-23 Halliburton Energy Sevices, Inc. Subterranean formation treatment fluids and methods of using such fluids
US7001872B2 (en) * 2001-06-11 2006-02-21 Halliburton Energy Services, Inc. Subterranean formation treating fluid and methods of fracturing subterranean formations
US6488091B1 (en) * 2001-06-11 2002-12-03 Halliburton Energy Services, Inc. Subterranean formation treating fluid concentrates, treating fluids and methods
US20030134298A1 (en) * 2001-07-03 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
AU2002365066A1 (en) * 2001-07-18 2003-07-09 American Red Cross Mutant proteinase inhibitors and uses thereof
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
CN1798838B (zh) * 2003-04-04 2012-01-04 洛桑大学 一种蛋白酶的抑制剂蛋白及其用途
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
BR112021012601A2 (pt) * 2018-12-28 2021-11-30 Catalyst Biosciences Inc Polipeptídeos ativadores de plasminogênio do tipo uroquinase modificados e métodos de uso
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CN112375131B (zh) * 2020-11-16 2021-10-01 西南大学 Seroin蛋白的截短体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112755A (en) * 1982-04-15 1992-05-12 Genentech, Inc. Preparation of functional human urokinase proteins
GR79202B (es) * 1982-05-05 1984-10-22 Genentech Inc
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US5073494A (en) * 1985-04-22 1991-12-17 Genentech, Inc. Human tissue plasminogen activator substituted at position 275 or at positions 275 and 277
JPH084501B2 (ja) * 1987-03-20 1996-01-24 エーザイ株式会社 糖鎖に関する変異ｔＰＡ
MY103358A (en) * 1987-04-15 1993-06-30 Novartis Ag Process for the production of protiens.
US5200340A (en) * 1987-05-22 1993-04-06 Zymogenetics, Inc. Thrombin-activated tissue plasminogen activators
NO882226L (no) * 1987-05-22 1988-11-23 Zymogenetics Inc Fibrinolytiske proteiner.
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5188829A (en) * 1987-08-19 1993-02-23 Sagami Chemical Research Center Rapidly acting prourokinase
WO1989007145A1 (en) * 1988-02-05 1989-08-10 Integrated Genetics, Inc. Modified gene sequences encoding modified tpa and products therefrom
EP0398962A1 (en) * 1988-02-05 1990-11-28 Genzyme Corporation Rearranged tissue plasminogen activators and method for producing same
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties

Also Published As

Publication number Publication date
JP3076035B2 (ja) 2000-08-14
AU5278090A (en) 1990-10-09
WO1990010649A1 (en) 1990-09-20
ATE226636T1 (de) 2002-11-15
AU637791B2 (en) 1993-06-10
ES2185529T3 (es) 2003-05-01
EP1029921A1 (en) 2000-08-23
DE69034013D1 (de) 2002-11-28
EP0462207A1 (en) 1991-12-27
JP3076034B2 (ja) 2000-08-14
JP2000037195A (ja) 2000-02-08
CA2047702C (en) 2000-10-24
EP0462207B1 (en) 2001-02-07
DK0462207T3 (da) 2001-06-18
DE69034013T2 (de) 2003-07-31
DE69033699T2 (de) 2001-05-23
JP2000078990A (ja) 2000-03-21
US5728564A (en) 1998-03-17
JP2991769B2 (ja) 1999-12-20
JPH04504952A (ja) 1992-09-03
DK1029921T3 (da) 2003-02-24
EP0462207A4 (en) 1992-06-24
DE69033699D1 (de) 2001-03-15
ATE199090T1 (de) 2001-02-15
EP1029921B1 (en) 2002-10-23
CA2047702A1 (en) 1990-09-07

Similar Documents

Publication Publication Date Title
ES2154629T3 (es) Mutantes t-pa resistentes a la inhibicion por sus inhibidores similares.
MY113489A (en) Reversible protease inhibitors
ES2066033T3 (es) Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ZA959819B (en) Substituted heterocylic compounds useful as inhibitors of (serine protease) human neutrophil elastase
NO930517L (no) Benzimidazolylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
PL319782A1 (en) Inhibitors of serinic proteases and anticoagulative protecins extracted from nematodes
ATE377006T1 (de) Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
DK501289A (da) Proteolytiske enzymer og deres anvendelse i vaskemidler
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
HUP0203130A2 (hu) Hexahidrofuro[2,3-b]furán-3-il-N-{3-(1,3-benzodioxol-5-il-szulfonil)-(izobutil)-amino-1-benzil-2-(hidroxi-propil)}-karbamát mint retrovírus-proteáz-gátló
HUP0003961A2 (hu) Kéztisztító készítmény
HK1016495A1 (en) Phosphorous-containing cysteine and serine protease inhibitors
DK0587799T3 (da) Inhibitorer af cathepsin G og elastase til forebyggelse af bindevævsnedbrydning
DE69832268D1 (en) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
IL122305A0 (en) Tace polypeptide its production and its use
FI962073A (fi) HIV-proteaasin estäjän prodrug-muotoja
EA199800200A1 (ru) Ингибиторы пролилэндопептидазы
ES2138624T3 (es) Combinaciones terapeuticas.
DE59812724D1 (de) Serin-proteinase-inhibitoren
PT666755E (pt) Inibicao da infeccao pelo vih
DE69227844D1 (de) Waschmittelzusammensetzungen
DK0828483T3 (da) Anvendelse af tropolonderivater som inhibitorer af enzymet inositolmonophosphatase

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 462207

Country of ref document: ES